Background and Purpose-Stroke is a leading cause of disability. Rehabilitation robotics have been developed to aid in recovery after a stroke. This study determined the additional cost of robot-assisted therapy and tested its cost-effectiveness. Methods-We estimated the intervention costs and tracked participants' healthcare costs. We collected quality of life using the Stroke Impact Scale and the Health Utilities Index. We analyzed the cost data at 36 weeks postrandomization using multivariate regression models controlling for site, presence of a prior stroke, and Veterans Affairs costs in the year before randomization. Results-A total of 127 participants were randomized to usual care plus robot therapy (nϭ49), usual care plus intensive comparison therapy (nϭ50), or usual care alone (nϭ28). The average cost of delivering robot therapy and intensive comparison therapy was $5152 and $7382, respectively (PϽ0.001), and both were significantly more expensive than usual care alone (no additional intervention costs). At 36 weeks postrandomization, the total costs were comparable for the 3 groups ($17 831 for robot therapy, $19 746 for intensive comparison therapy, and $19 098 for usual care). Changes in quality of life were modest and not statistically different. Conclusions-The added cost of delivering robot or intensive comparison therapy was recuperated by lower healthcare use costs compared with those in the usual care group. However, uncertainty remains about the cost-effectiveness of robotic-assisted rehabilitation compared with traditional rehabilitation. Clinical Trial Registration-URL: http://clinicaltrials.gov. Unique identifier: NCT00372411.
R ehabilitation robotics have been developed to aid in rehabilitation, alter the physical burden on a therapist, and potentially improve a clinic's productivity. Such technologies have led to modest improvements in functioning among patients with chronic upper-extremity disability related to stroke. 1, 2 This study determined whether cost differences would favor robot-assisted treatment compared with more conventional therapies for patients with stroke with a moderate to severe upper-extremity impairment.
Methods

Study Overview
In a 3-arm randomized controlled trial (VA ROBOTICS), we enrolled patients whose stroke caused moderate to severe upperextremity impairment and predated the study entry by Ͼ6 months. 3 Patients were randomized to usual care plus robot-assisted therapy, usual care plus intensive comparison therapy, or usual care alone. Intensive comparison therapy mirrored the intensity, frequency, and type of movements of robot-assisted therapy. 4 Both robot and intensive comparison therapy involved 3 1-hour sessions per week for 12 weeks. Details on the study design are presented elsewhere. 5 
Data
We tracked participants' use of Veterans Affairs (VA) inpatient care, outpatient care, and costs in the Patient Treatment File and National Patient Care Database and the Decision Support System, respectively. Non-VA use and use of formal and informal caregiving were tracked with case report forms. We calculated the travel distance from the patient's home zip code to the medical center's zip code. Quality of life was assessed using the Health Utilities Index, 6 a Feeling Thermometer, and the Stroke Impact Scale. 7 
Analysis
We used multivariate regression models controlling for site, presence of a prior stroke, VA costs in the year before randomization, and Charlson Comorbidity Index in the year before randomization. 8 We compared costs and quality-adjusted life-years, based on the Health Utilities Index, using an incremental cost-effectiveness ratio based on the 36-week data.
Results
Sample Characteristics
There were no significant differences among the 3 groups in baseline demographics or the use of the VA system in the year before enrollment, except time from the index stroke to randomization, which was significantly longer in the usual care group. 2 
Intervention Costs
The cost per session of robot and intensive comparison therapy was estimated at $140 and $218, respectively. The unadjusted average cost of the intervention over the 12-week treatment period was $5152 for the robot and $7382 for intensive comparison therapy (PϽ0.001; see http://stroke.ahajournals.org for the detailed results).
Costs and Outcomes at 36 Weeks
The analyses identified no significant differences among the 3 groups' VA use, non-VA use, or patient-incurred costs at 36 weeks. Total healthcare costs (excluding intervention costs) at the end of the 36 weeks averaged $12 679 for the robot group, $12 364 for the intensive comparison therapy group, and $19 098 for the usual care group. Although the average costs for the usual care group were higher than the other groups, the data were skewed, which is evident when we compare the median costs of the robot ($5541), intensive comparison therapy ($6912), and usual care group ($6799; see http://stroke.ahajournals.org for the detailed results).
Self-reported functioning and quality of life did not significantly differ among the 3 groups over time, except for the Stroke Impact Scale, in which the robot group had a significantly higher score than the usual care group at 12 weeks (Pϭ0.04). This difference decreased over time and was not significant at 24 or 36 weeks.
VA Costs After 36 Weeks
After the trial ended at 36 weeks, we tracked use of VA health care and mortality through the end of Fiscal Year 2009 (September 30, 2009) for participants in the 2 active control groups (following usual care patients was not possible because at 36 weeks, they could elect robot or intensive comparison therapy). For the robot group, VA health care averaged $7777, whereas the intensive comparison therapy group averaged $14 513 (Pϭ0.04). When healthcare and travel costs were combined, the difference was not statistically significant (Pϭ0.06). The total cost from randomization through the end of Fiscal Year 2009 averaged $25 608 for the robot group and $34 259 for the intensive comparison therapy group (Pϭ0.21; see http://stroke.ahajournals.org).
Incremental Cost-Effectiveness Ratio
At 36 weeks, the robot group had a lower average cost ($1267) and an increase in quality-adjusted life-years (0.049) relative to the usual care group. However, the large standard errors around effectiveness and costs yielded an incremental cost-effectiveness ratio with a wide bootstrapped confidence region (Ϫ$450 255, ϩ$393 356).
Discussion
Improvements as measured by the Stroke Impact Scale were significantly better at 12 weeks for the robot versus usual care, but these differences were not maintained over 24 and 36 weeks. At 36 weeks, the average costs were not significantly different among the 3 groups. After 36 weeks, the robot group used less VA care and had an average cost that was less than the intensive comparison therapy group.
One limitation of this trial is the sample size. Although larger than many other robot studies, it is small for analyzing cost data. Also, the predominantly male sample, although representative of the VA, may limit the generalizability of the results to women.
The use of robotic technology for stroke rehabilitation is a rapidly growing area. The VA ROBOTICS study demonstrated modest clinical benefit for robot-assisted therapy compared with usual care at 36 weeks. Although providing additional care using new technology can be expensive, the total costs, which include therapy and healthcare costs, were not greater for the robot group than the usual care group. Patients in the robot and intensive comparison groups had lower average costs than patients in usual care group. From a healthcare system perspective, this suggests an offset in the system, which will require studies with larger samples to fully understand. 
Sources of Funding
Supplemental Methods
We recruited eligible veterans from four VA medical centers (Baltimore MD, West Haven CT, Gainesville FL, and Seattle WA). Eligibility was limited to patients who had a moderate-tosevere upper limb motor impairment from a stroke that occurred at least 6 months prior to enrollment. We measured impairment using the Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke, 1 and patients with a Fugl-Meyer score of 7 to 38 were eligilble. All sites received IRB approval and patients provided written informed consent. More details on the study methods and main results are reported elsewhere. 2, 3 Data We merged the utilization and cost data using date of service and location of service. The Decision Support System (DSS) is an activity-based cost accounting system and is considered the gold standard for health care cost estimates. 4 We also merged the datasets to the Health Economics Resource Center (HERC) Average Cost data. [5] [6] [7] The HERC average cost data are based on non-VA relative weights. Chapko et al. 8 found high concordance between the DSS and HERC data, although the data can be used together to identify outliers. We used the HERC data in a sensivity analysis (see below).
Missing data were relatively infrequent at baseline (<3%) but increased at the follow-up time points: 12 weeks (<10%), 24 weeks (<20%), 36 weeks (<12%). Missing data were more common in the intensive comparison therapy group than the other two groups; however, this imbalance was not statistically significant. We used multiple imputation methods to account for missing data.
Surveys were used to gather use of non-VA care. Fourteen participants reported that their spouse provided care 24 hours a day, 7 days a week; we estimated these caregiving costs based on a 12-hour work day.
Intervention Costs Therapists were involved in both the robot-assisted and intensive comparison therapy sessions. We did not track the amount of time therapists spent with patients while patients used the robot. These time estimates would not be representative of how the robots would be used in routine clinical care. According to the US Preventive Services Task Force's recommended methods for cost-effectiveness analyses, 9 the relevant prices and units should be based on how the intervention will be used in routine practice, assuming efficient production at constant returns to scale. Therefore, we estimated the therapist time based on discussions with the therapists. The therapists thought that 15-minutes of a one-hour robot rehabilitation session would involve direct patient contact. We estimated therapist costs by analyzing FY2008 VA cost and utilization data. We identified stroke patients receiving outpatient physical and occupational therapy in VA. We analyzed therapy costs by the number of minutes of therapy, identified by rehabilitation Current Procedure Terminology (CPT) codes. For the 60-minute robot sessions, we estimated that 15 minutes would involve direct patient contact with a therapist at a cost of $120. The cost per intensive comparison therapy session was $218, based on 60 minutes of rehabilitation time with the therapist. Overhead and fixed expenses are disproportionately attributed to the first 15 minutes, explaining why 15 minutes costs $120, while sixty minutes costs $218.
In addition to the personnel time, a robot session includes the capital cost of the robot. We estimated the cost per robot session using its purchase price ($230,750), an annual maintenance contract ($15,000), financing at an annual rate of 6.015%, and 33% for facility overhead. 10 We assumed that the robots had a 5-year life span and estimated the net present value of the robot ($422,532), which we then divided by the number of sessions in five years.
It was determined that a single site could offer seven sessions per day Monday through Friday and four sessions on Saturday and Sunday with one robot. Each session includes 60 minutes of rehabilitation time plus 15 minutes for set up and clean up. The robot system consists of three separate stations, and up to three patients can use the robot concurrently, much like a gym. In the base case, we assumed that two patients would concurrently use the robot. Under these conditions, a site could offer 86 treatment sessions per week or 4,300 sessions per year (includes two weeks of downtime), and the estimated cost of the robot (i.e., equipment cost only) was $20 per session. When combined with the personnel costs, the additional cost of a robot session was $140 as compared to intensive comparison therapy ($218). Everyone continued with usual care, so the added cost of usual care was $0.
The intensive comparison therapy group incurred some expenses related to rehabilitation supplies and materials (approximately $3000 per site). Many rehabilitation clinics already have these tools, so we did not include these costs in the analysis.
Analysis
Our cost analyses used a societal perspective, which considered all costs irrespective of who paid for them. We standardized costs to 2009 dollars using the general Consumer Price Index instead of the Medical Care Price Index, which can overestimate inflation costs. 11 We also adjusted the costs for local wage differences using the Medicare wage index, which estimates the average labor costs in a geographic market. 12 We analyzed costs using multivariate regression models while controlling for site, presence of a prior stroke, VA costs in the year prior to randomization, and Charlson Co-morbidity Index in the year prior to randomization. 13 The Comorbidity Disease Index, 14 which was used in the primary outcomes paper, 3 predicts functional decline. In this paper, we used the Charlson Index because we wanted to control for other comorbidities that could affect utilization, costs or mortality. We tested three alternative models for analyzing the cost data: linear models, log transformed costs (semi-log), and general linear models (GLM). For the general linear model, the distributional choice was based on the modified Park test. 15 We used the Linktest 16 and Hosmer and Lemeshow 17 goodness of fit tests to identify the best fitting model.
We analyzed use of any inpatient care with logistic regression and the number of outpatient visits with negative binomial regression. 18 In a subgroup analysis, we assessed whether the intervention had a differential effect for people with more severe self-reported physical limitations. We compared costs for people whose baseline SIS was <50 (more limited) compared to those whose baseline SIS was ≥50 (less limited). The cut points were chosen to make equally sized groups, and also happened to be in the middle of the 0-100 range for the scale; the subgroup analysis was exploratory given it was not planned a priori and there was limited power given the small sample size.
We computed the incremental cost-effectiveness ratio (ICER):
(Avg Cost robot -Avg Cost usual care ) / (Avg QALY robot -Avg QALY usual care ) Following Glick et al, 19 we calculated Fieller 95% confidence region around the ICER, the bootstrapped 95% confidence region based on 4,000 replications, and the willingness to pay for an ICER.
Sensitivity Analysis 1) The primary analyses used DSS cost data. We re-tested our analysis with the HERC Average Cost datasets, which are based on non-VA (e.g., Medicare) relative value units. 2) Because the robot is relatively new and it is not clear how clinics will use it in practice, we varied the number of patients that would use the robot.
3) The primary analysis assumed that therapists would spend 15 minutes with a patient during a 60 robot session and use the remaining 45 minutes in another productive capacity. In a sensitivity analysis, we assumed that a robot session used 30 minutes of therapist time. 4) We tested whether changes in the discount rate would affect the results. 5) We ran the model with alternative prices for non-VA care. 6) For the HUI and SIS, we used fractional logit models because the linear models does not account for the fact that these outcomes have maximum and minimum bounds.
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Supplemental Results
There were no significant differences across the three groups in baseline demographics or the utilization of the VA system in the year prior to enrollment (Supplemental Table 1 ). The average participant age was 66, 64 and 63 in the robot, intensive comparison therapy and usual care groups, respectively. Consistent with the population of older Veterans, most participants (96%) were male. As presented elsewhere, the groups had similar clinical characteristics, with the exception of time from index stroke to randomization, which was significantly longer in the usual care group. 3 
Intervention Costs
The unadjusted average cost of the intervention over the 12 week treatment period was $5,152 for the robot and $7,382 for intensive comparison therapy (Supplemental Table 2 ); this difference was statistically significant (p<0.001). All participants continued with their usual care, which we included with the participants' cost at 36 weeks.
Costs and Outcomes at 36 Weeks
The analyses identified no significant differences in the three groups' VA utilization, non-VA utilization, or patient incurred costs (Supplemental Table 3 ). Total health care costs (excluding intervention costs) at the end of the 36 weeks averaged $12,679 for the robot group, $12,364
for the intensive comparison therapy group, and $19,098 for the usual care group. Although the average costs for the usual care group was higher than the other groups, the data were skewed, especially for the usual care group. This skewness becomes apparent when we compare the median costs for the robot ($5,541), intensive comparison therapy ($6,912) and usual care groups ($6,799).
When we combined the intervention costs and health care costs, the total cost was $17,831 for the robot group, $19,746 for the intensive comparison therapy group and $19,098 for the usual care group (Supplemental Table 3 ). These cost differences were not statistically different in the OLS model, which fit the data better than the GLM or semi-log model (Supplemental Table 4 ).
VA health care costs after 36-weeks were significantly lower for the robot group than the intensive comparison therapy group (p=.04; see Supplemental Table 5 ). When we included travel costs, the difference was not significant (p=.06). When we considered all costs from randomization through Sept 30, 2009, the robot group was not significantly different from the intensive comparison therapy group (p=.21).
Self-reported functioning and quality of life did not significantly differ among the three groups over time (Supplemental Figure 1) . The one exception was for the SIS. At twelve weeks, the robot group had a significantly higher score on the SIS than the usual care group (p=0.04). This difference decreased overtime and was not significant at 24 or 36 weeks. We analyzed those with a mild stroke (a SIS score >=50) and compared them to those with severe stroke (a SIS score <50), and there was no evidence that the intervention effect varied by SIS score (results not shown).
Compared to usual care, the incremental cost for the robot was -$1,267 (SE $5,586) and the incremental gain in QALYs was .04915 (SE .0692). This yielded an incremental costeffectiveness ratio of $-25,770, suggesting dominance of the robot over usual care. The large standard errors created substantial uncertainty in the confidence regions. We could not compute Feiller 95% confident regions given the standard errors. In addition, the bootstrapped 95% confident region was very large (-450,255 -393,356). Therefore, there was no willingness to pay threshold for which we could be 95% confident that the robot was more cost-effective than usual care.
Sensitivity Analyses 1)
The average cost of a rehabilitation visit with 15 and 60 minutes of therapy cost $120 and $218, respectively, from the DSS data. For the same visits, HERC cost estimates were lower: $91 and $155, respectively (see Supplemental Table 7 ). However, the results were not sensitive to the source of VA cost data (DSS versus HERC). 2) Our primary analysis was based on a clinic running 43 robot sessions a week with 2 patients per session; in this situation, therapy would cost $5,152 (Supplemental Table 3 ). If the clinic had enough patients to schedule 3 patients per session (the maximum possible) with 52 sessions per week, then therapy would cost $4,856 (a 6% reduction). However, if a clinic used the robot less efficiently, then the cost per session increased. For example, if the clinic had one patient use the robot per session and offered 38 sessions per week, then the cost of therapy and the total cost would be $5,939 (a 15% increase). None of these changes, however, resulted in a statistically significant difference between the robot and the other two groups. 3) Our primary analysis assumed that a session of robot therapy would involve 15 minutes of therapist time at an cost of $120; in this situation, three one-hour sessions per week for twelve weeks cost $5,152. If a therapist spent 30 minutes with the patient, at a cost of $152, then therapy would cost $6,202 (a 20% increase). This change, however, did not affect the statistical significance of the results. 4) Changing the discount rate had very little affect on the results because the robot's lifespan was relatively short. Moving from a 5% to 7% or 3% had very little effect. Likewise, changing the interest rate also had very little effect on the results. 5) The groups did not differ in their use of non-VA costs, and the results were not sensitive to the ±50% changes in the unit costs of non-VA care. 6) Fractional logit models analyzing quality of life produced results that were consistent with the linear models.
In summary, the results were most sensitive to how efficiently the clinic used the robot and the time the therapist spent with the patient during a robot session.
While benefits from an intervention can sometimes vary by disease severity, analyzing the data by subgroups showed little evidence to suggest that persons with more severe physical limitations, as measured on the SIS, benefited more from the robot therapy compared to intensive comparison therapy or usual care. These subgroup analyses should be viewed with caution because they were conducted post-hoc, making them more unreliable.
We did not create a lifetime cost-effectiveness model because the 36-week data showed no significant differences in the ICER between the robot and usual care. We observed differences between the robot and the intensive comparison therapy groups after 36 weeks, but could not include the usual care comparison group because patients in this group were allowed to selfselect either robot or intensive comparison therapy at 36 weeks.
Supplemental Discussion
There are a number of factors that health care decision makers should consider before deciding whether to invest in robot-assisted rehabilitative equipment. First, it is important to consider the size of the population that will use the robot and how efficiently the clinic can utilize the robot. Health care systems that buy a robot are making a large investment and facilities should determine whether they have sufficient patient flow to keep the machine fully utilized. In our analyses, a clinic would need 131 eligible patients to utilize the robot efficiently; an eligible patient is one with a chronic stroke impairment and a Fugl-Meyer Assessment score of 7-38. Second, the robots purchased for this study cost $230,750, but the price could decrease in the future through scale economies (the marginal cost decreases as production expands) or additional competition. Third, we analyzed quality of life as our primary clinical outcome. However, a wide variety of other factors may be relevant in the decision to purchase a robot.
For example, a hospital might purchase a robot to maintain its reputation as a technology leader in treating stroke patients, or as a novel way to encourage more patients to get poststroke rehabilitation in its facilities. Our study did not evaluate these outcomes. However, if a decision maker is only concerned with improving patient outcomes, as measured with the Stroke Impact Scale or Health Utilities Index, or cost-effectiveness, then our results do not favor one approach. Presented are the best fitting models according to goodness of fit tests ^ p=.06 * significant at 5%; ** significant at 1%, two tailed test +Coefficient is small and rounds to zero.
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